Open AccessSafety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression
Author(s) -
Saby George,
Robert J. Motzer,
Hans J. Hammers,
Bruce G. Redman,
Timothy M. Kuzel,
Scott S. Tykodi,
Elizabeth R. Plimack,
Joel Jiang,
Ian M. Waxman,
Brian I. Rini
Publication year - 2016
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2016.0775
Subject(s) - medicine , nivolumab , response evaluation criteria in solid tumors , renal cell carcinoma , progression free survival , oncology , tumor progression , immunotherapy , randomized controlled trial , clinical trial , phases of clinical research , urology , cancer , chemotherapy
Response patterns with immunotherapy may differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom